Inhibikase Therapeutics (IKT) Common Equity (2020 - 2026)

Inhibikase Therapeutics (IKT) has reported Common Equity for 7 consecutive years, with $167.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity rose 95.52% year-over-year to $167.6 million; the TTM figure through Mar 2026 stood at $167.6 million (up 95.52% YoY), while the FY2025 annual figure was $172.9 million, up 82.26% from the prior year.
• Common Equity retreated to $167.6 million in Q1 2026 per IKT's latest filing, from $172.9 million in the prior quarter.
• Across five years, Common Equity topped out at $172.9 million in Q4 2025 and bottomed at -$530591.0 in Q3 2024.
• Historically, Common Equity has averaged $50.9 million across 5 years, with a median of $25.3 million in 2023.
• Annual changes were most pronounced in 2024 — Common Equity sank 103.53% — and 2025, when it surged 13839.08%.
• Inhibikase Therapeutics' Common Equity stood at $21.0 million in 2022, then sank by 47.81% to $11.0 million in 2023, then soared by 764.16% to $94.9 million in 2024, then soared by 82.26% to $172.9 million in 2025, then declined by 3.06% to $167.6 million in 2026.
• Business Quant data shows IKT's Common Equity at $167.6 million in Q1 2026, $172.9 million in Q4 2025, and $72.9 million in Q3 2025.